$VBLT News
Last published 3y ago
- 3y agoVBLTNotable Labs Closes Merger Transaction With VBL TherapeuticsGlobeNewswire- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 -
- 3y agoVBLTVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingGlobeNewswireApproved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate
- 3y agoVBLTVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingGlobeNewswireMODI'IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), reminds its shareholders to vote in favor of the previously announced proposed merger (the "Merger") with Notable
- 3y agoVBLTVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECGlobeNewswireMerger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI'IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL
- 3y agoVBLTVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireMerger with Notable expected to close in late September or October, subject to VBL's S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30,
- 3y agoVBLTVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireMODI'IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.
- 3y agoVBLTVBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireMODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update. "I
- 3y agoVBLTVBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in CashGlobeNewswireMODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi'in, Israel, and
- 3y agoBTERADITCRRVBLTMoore Kuehn Encourages VBLT, RADI, TCRR, and BTE Investors to Contact Law FirmGlobeNewswireNEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoVBLTAleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster PartnershipBusiness WireEfficient capital deployment in Israel and Singapore designed to support scale-up in key markets Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today announced that it
- 3y agoINDTJNCEPTRSVBLTMoore Kuehn Encourages PTRS, VBLT, INDT, and JNCE Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoVBLTVBL Therapeutics and Notable Labs Announce Definitive Merger AgreementGlobeNewswireMerger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Medicines Platform
- 3y agoVBLTVBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in CashGlobeNewswireMODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced today that it has entered
- 4y agoVBLTVBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireTEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced that VBL received a written notification (
- 4y agoVBLTVBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic OptionsGlobeNewswireTEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the second quarter ended June
- 4y agoVBLTVBL Therapeutics Announces Workforce ReductionGlobeNewswireTEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed
- 4y agoVBLTVBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian CancerGlobeNewswireTEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced top-line data from the Phase 3 OVAL clin
- 4y agoVBLTVBL Therapeutics to Participate in the Jefferies Healthcare ConferenceGlobeNewswireTEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflamm
- 4y agoVBLTVBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireOVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIR
- 4y agoVBLTVBL Therapeutics to Report First Quarter 2022 Financial Results on May 17GlobeNewswireTEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or in
- 4y agoVBLTVBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in MayGlobeNewswireTEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or in
- 4y agoVBLTVBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireTEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammator
- 4y agoVBLTVBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian CancerGlobeNewswireFDA grants Fast Track designation to facilitate development and expedite the review of therapies with potential to treat serious unmet medical needs. The purpose of this designation is to bring important new drugs to patients earlier OVAL Phase 3 t
- 4y agoVBLTVBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireOVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023 Completed patient enrollment in the 409 patient OV
- 4y agoDRTSMACAVBLTAlpha Tau Medical Ltd. Appoints Ruth Alon to its Board of DirectorsPR NewswireJERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective im
- 4y agoVBLTVLB Therapeutics to Report Year-End 2021 Financial Results on March 23GlobeNewswireTEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or
- 4y agoVBLTVBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as PlannedGlobeNewswirePhase 3 OVAL trial enrolled 409 patients globally at centers in the United States, Europe, Israel, and Japan Top-line data from progression free survival (PFS) primary endpoint expected in 2H 2022 expected to have the potential to support a Biologics L
- 4y agoVBLTVBL Therapeutics to Participate at March Investor ConferencesGlobeNewswireTEL AVIV, Israel and NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflamma
- 4y agoVBLTVBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireTEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory
- 4y agoVBLTVBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor ConferenceGlobeNewswireTEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory
- 4y agoVBLTVBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial OfficerGlobeNewswireCCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; P
- 4y agoVBLTVBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual ConferenceGlobeNewswireTEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory indicat
- 4y agoVBLTVBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator ProgramGlobeNewswireVBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL AVIV, Israel and NEW YORK, Dec. 20, 2021 (GLOBE NE
- 4y agoVBLTVBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireConference Call and Webcast at 8:30 a.m. ET Today Data from multiple VB-111 clinical trials expected in 2022, including the progression free survival (PFS) co-primary endpoint from the Phase 3 OVAL study expected in the second half of 2022 More than
- 5y agoVBLTVBL Therapeutics to Report Third Quarter Financial Results on November 15GlobeNewswireTEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, tod
- 5y agoNBSEVBLTVBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United StatesGlobeNewswireTEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate financ
- 5y agoVBLTVBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian CancerGlobeNewswireThe OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date; Remains on track to complete enrollment in 1Q22 TEL AVIV, Israel, Sept. 17, 2021 (GLOBE NEWSWIRE) --
- 5y agoVBLTVBL Therapeutics to Present at Upcoming ConferencesGlobeNewswireTEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd Annual Global Investment Conference Mon., Sept. 13, 202
- 5y agoVBLTVBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin FacilityGlobeNewswireU.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercialization OVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer has recruited nearly 80% of target enrollment; rema
- 5y agoVBLTVBL Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireConference Call and Webcast at 8:30 a.m. EDT Today ● Closed public offering raising net proceeds of $26.4 million; cash position is expected to fund operations until year-end 2023, through readout from the OVAL study and potential Biologics Lice
- 5y agoVBLTVBL Therapeutics to Report Second Quarter Financial Results on August 16GlobeNewswireTEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive
- 5y agoVBLTVBL Therapeutics Appoints Marc Kozin as Chairman of its Board of DirectorsGlobeNewswireTEL AVIV, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the planned elevation of Marc Kozin as chairman of the company's board of directors. Bennett Shapiro, M.D., has stepped down from his chairman role but r
- 5y agoAFIBNOKTALVBLT+1Thinking about buying stock in Xeris Pharmaceuticals, Acutus Medical, Vascular Biogenics, Nokia, or TAL Education Group?PR NewswireNEW YORK, July 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XERS, AFIB, VBLT, NOK, and TAL. To
- 5y agoVBLTVBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of DirectorsGlobeNewswireTEL AVIV, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021. Professor Ruth Arnon has stepped down from her role
- 5y agoVBLTVBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian CancerGlobeNewswireTEL AVIV, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. The
- 5y agoVBLTVBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian CancerGlobeNewswireSecond primary endpoint added following discussion with the U.S. Food and Drug Administration Successfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA for potential full FDA approval PFS endpoint readout e
- 5y agoVBLTVBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireTEL AVIV, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in ovarian cancer will be presented at the American S
- 5y agoVBLTVBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireConference Call and Webcast at 8:30 a.m. EDT Today OVAL Phase 3 registration-enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer remains on track in spite of COVID-19, with over 260 patients enrolled; next DSMC revi
- 5y agoVBLTVascular Biogenics Ltd. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 11, 2021 / Vascular Biogenics Ltd. (NASDAQ:VBLT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 8:30 AM Eastern Time. To listen to the event live or acces
- 5y agoVBLTVBL Therapeutics to Report First Quarter Financial Results on May 11GlobeNewswireTEL AVIV, Israel, May 04, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open. Professor Dror Harats, M.D, Chief Execut